Medeon Biodesign (6499.TWO) Stock Price

Medeon Biodesign Price

CLOSED
79.20
​
Market closed

Revenue has compounded at 34.4% per year over the past 9 years to 419.43 M TWD. Medeon Biodesign's net margin stands at -159.3%, down from 3,013.8% several years earlier. Medeon Biodesign currently offers a dividend yield of about 0.63%. Analysts set a median price target of 211.44 TWD, implying 167.0% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

Medeon Biodesign stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeon Biodesign business model & stock analysis

Medeon Biodesign Inc, headquartered in Taipei City, Taiwan, develops, manufactures, and sells medical equipment. Listed on 11 December 2014, the company specializes in medical apparatus and instruments for laparoscopic and cardiac catheter minimally invasive surgeries. Its products are distributed domestically and internationally, serving the Health Care sector with innovative surgical solutions.

Frequently asked questions about Medeon Biodesign

Analysts currently set an average price target of 211.44 TWD for the Medeon Biodesign stock (median: 211.44 TWD), implying +167.0 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Medeon Biodesign stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Medeon Biodesign to generate revenue of 461.00 M TWD and earnings per share of -7.33 TWD.

Converted at the current exchange rate, the Medeon Biodesign share trades at 2.17 EUR (79.20 TWD).

The expected revenue of Medeon Biodesign is 461.00 M TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medeon Biodesign is -710.57 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medeon Biodesign is currently -10.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medeon Biodesign stock.

The price-to-sales ratio (P/S) of Medeon Biodesign is currently 16.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medeon Biodesign stock.

The Eulerpool Quality Score for Medeon Biodesign is 3/10.

The ISIN of Medeon Biodesign is TW0006499007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Medeon Biodesign is 6499.TWO. The ticker symbol is used to trade Medeon Biodesign shares on the stock exchange.

Fair ValueTerminal
79.20 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Dec 11, 2014
ISIN
TW0006499007
Cusip
Y59446107
Market capitalization
7.68 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-10.81
P/Ee 2027
26.85
P/Se
16.66
EV/EBIT
—
P/B Ratio
5.20
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-45.27 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
0.63 %
Payout Ratio
0.00 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
21.00 %
Last updated Oct 24, 2026, 1:11 PM

Medeon Biodesign Peer Group

Medeon Biodesign FIGI

6499:TT (Taipei Stock Exchange) · BBG007NPQT83